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EDITORIALS
Despite increasing provision of school sex education, 
teenage sexual health in the United Kingdom is in over-
all decline, with increasing rates of terminations and 
sexually transmitted infections in under 18s outweigh-
ing recent modest reductions in conception rates in this 
age group.1 2 w1
Counterintuitively, rather than improving sexual 
health, sex behaviour interventions can make it worse.w2 
Most studies on sex education programmes in schools 
examine intermediate outcomes only, such as pupil 
satisfaction or reported condom use. This often facili-
tates premature false claims of success, whereas more 
robust outcome measures such as rates of terminations, 
unplanned conceptions, and sexually transmitted infec-
tions show no benefit.
In this week’s BMJ Henderson and colleagues report 
the effect of a theoretically based teacher delivered sex 
education programme (SHARE) on registered concep-
tions and terminations.3 The trial found no significant 
difference between the intervention and control groups 
in National Health Service registered conceptions (per 
1000 pupils: 300 SHARE v 274 control; difference 26, 
95% confidence interval !33 to 86) or terminations (127 
SHARE v 112 control; difference 15, !13 to 42) between 
ages 16 and 20.
The results should stimulate urgently needed change 
from previous ineffective approaches to school sex edu-
cation for which, as the authors admit, “evidence of 
effectiveness is mixed.” Evidence shows that increased 
knowledge is a necessary but insufficient cause of change 
in sexual behaviour.w3 It is also clear that strategies such 
as promoting availability and correct use of condoms and 
increasing use of the emergency pill do not necessarily 
lead to a reduction in sexually transmitted disease rates,1 
pregnancies,w4 or terminations.4
So what needs to happen next? Henderson and 
colleagues stress the need for more comprehensive 
approaches that incorporate the influence of parents on 
sexual experience in teenagers, and to improve the future 
life opportunities for vulnerable young people. The false 
assumption that “young teens will have sex anyway” is 
an insult to many young people who have the capacity 
to rise to a far more effective challenge than just “use a 
condom every time.”
Delaying first intercourse is recognised as an impor-
tant outcome measure of sex education programmes, and 
teenagers are more likely to save sex (a more positive 
and helpful term than “abstinence”) when their parents 
communicate the importance of doing so.5 Of course, 
to be involved in this way, parents have to be with their 
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children.w5 Much evidence points to the effectiveness of 
maternal involvement in sex education.6 However, the 
presence of a father is also an important factor in teen-
agers saving sex until adulthood.w6 In the Netherlands, 
many more mothers and fathers talk with their children 
about sex than in the UK.7 The lower rate of single par-
enthood in the Netherlands is an important factor in the 
lower rate of teenage pregnancy seen in that country.7 
Giving students homework to complete with their par-
ents greatly enhanced the effectiveness of one school 
based abstinence only programme.8 This study, how-
ever, measured the usual intermediate outcomes only, 
such as self efficacy and intention to have sex, and more 
randomised controlled trials of abstinence programmes 
are needed to look at effects on sexual debut, unplanned 
conceptions, and sexually transmitted infections.
Much teenage sex has little to do with sex itself but 
is connected with searching for meaning, identity, and 
belonging.w7 These wider sociocultural aspects influ-
encing sexual behaviour need greater attention.9 Their 
importance is highlighted by a Seattle community 
based programme for children up to age 12, designed to 
help avoid health risk behaviours in later adolescence. 
Though good social decision making (including abstain-
ing) in areas such as conflict resolution or drug use was 
encouraged, this programme contained no specific sex 
education. Nevertheless, at nine year follow-up, peo-
ple in the programme were significantly older at first 
sexual experience and were significantly less likely to 
become pregnant by age 21 (38% v 56%; P <0.05, 95% 
confidence interval 0.27 to 0.93).10 A key factor in the 
Ugandan success in reducing HIV rates so dramatically 
during the 1990s was a community wide, mass media 
communication of messages to achieve the desired out-
comes of abstinence and being faithful, in addition to 
condom use.w8 w9
Blanket assertions that abstinence programmes 
“don’t work” abound.w10 Ironically, however, the only 
randomised trial of school sex education identified by 
the SHARE team to use clinical data on pregnancies 
was of an abstinence only programme that resulted in a 
significant reduction of pregnancies.11 With the introduc-
tion of its recent “Leave it till later” campaign, the UK 
government is belatedly recognising that saved sex is a 
vital component of truly safer sex. In the United States, 
teenage pregnancies are at their lowest level in more than 
30 years, and the teenage abortion rate has been halved 
since its peak in 1988. The only peer reviewed studies of 
reasons for these trends published up to 2006 attribute 
two thirds of the teen pregnancy reduction in unmarried 
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teenage girlsw11 and just over half of the total reduction to 
delayed first sex.12 With a recent study showing that edu-
cation to save sex does not lead to decreased condom 
use at first sex,w12 it is time the evaluation of saved sex 
programmes had a share of UK funding for sex educa-
tion research. However, if saving sex is seen as a way for 
young people to avoid unplanned pregnancy more than 
just an educational structure, then last week’s govern-
ment announcement of plans to raise the school leaving 
age to 18 should do more to reduce teenage pregnancy 
rates than anything they have done so far.w13
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In this week’s BMJ Sazawal and colleagues report a trial 
of milk fortified with multiple micronutrients (as a strat-
egy to deliver zinc and iron) in children in India.1 They 
found a significant reduction in severe illness and the 
incidence of acute respiratory infections and diarrhoea. 
Although data on the impact of the intervention on iron 
and zinc status are not presented, the functional benefits 
are consistent with the previously recognised benefits 
of zinc supplementation on the burden and severity of 
diarrhoeal diseases and respiratory infections.2
Iron deficiency ranked ninth among 26 risk factors 
included in the global burden of disease study, and 
accounted for 841 000 deaths and 35 057 000 disability 
adjusted life years lost.3 Large sections of populations in 
Africa and Asia are at risk of dietary zinc deficiency and 
resulting high rates of stunting.4 Correcting micronutri-
ent deficiencies can help reduce child mortality,5 but 
it is unclear how these deficiencies can be dealt with 
at the population level. Although combinations of iron 
and zinc have been suggested as appropriate strategies 
for rectifying deficiencies of multiple micronutrients in 
children at risk, the benefits may not be additive because 
of potential interactions.6
Despite promotion of micronutrient supplements,7 
evidence from many supplementation trials in children 
is mixed. Some trials using dispersible tablets contain-
ing multiple micronutrients have found no significant 
benefits on functional outcomes.8 One study in children 
in Peru with persistent diarrhoea found higher rates of 
diarrhoea, respiratory infections, and febrile episodes in 
the children who received multiple micronutrients and 
zinc compared with those given zinc supplementation 
alone.9 However, in Karachi daily micronutrient and 
zinc supplementation reduced rates of diarrhoea.10 The 
findings from a recent large scale trial of iron and zinc sup-
plementation in a malaria endemic area in Zanzibar are 
more worrying.11 In this trial, which compared daily iron 
and folic acid with iron and folic acid and additional zinc 
or placebo in infants, the iron and folic acid supplemen-
tation arms were stopped early because of a significantly 
higher rate of mortality and hospital admission.
These data have raised concerns about the safety of 
large scale iron supplementation programmes in malaria 
endemic areas, and highlighted the need for alternative 
strategies to deal with deficiencies in iron and other micro-
nutrients in children at risk. These include fortification 
of commonly consumed foods, condiments, and staples 
such as wheat flour. These may be useful for adults, but 
because of the limited consumption of some of these foods 
by young infants and children, they may not be the most 
effective means of delivering recommended amounts of 
micronutrients.
An alternative strategy might be to fortify commonly 
consumed centrally processed complementary or wean-
ing foods. However, the availability and cost of such 
foods in developing countries precludes their wide-
spread use. Alternative strategies include the addition 
of microencapsulated forms of iron and other micro-
nutrients in the form of “sprinkles” (sachets of fortified 
powder) to commonly used foods available at home.12 
Although sprinkles are generally added to foods, much 
effort may be needed to induce behaviour change and 
to monitor changes. 
Fortification of commonly used food items for 
children, such as milk, offers an attractive alternative. 
Sazawal and colleagues’1 finding of the acceptability 
of fortified milk as a delivery vehicle are supported by 
similar findings from Mexico.13 In the Mexican study 
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Tuberculosis in resource poor countries
Better access to antiretroviral therapy and isoniazid prophylaxis offer new 
opportunities for control
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cal models have suggested it has limited potential to 
reduce the burden of tuberculosis within the general 
population.3 However, these models did not take into 
account the potential effect of antiretroviral therapy on 
the health seeking behaviour of populations with a high 
seroprevalence of HIV.
Better access to antiretroviral therapy makes people 
more willing to be tested for HIV.6 This has resulted 
in a greater awareness of HIV and a reduction in the 
stigma associated with the disease.7 Moreover, voluntary 
counselling and testing sites are suitable places to screen 
for tuberculosis and initiate tuberculosis chemoprophy-
laxis.8
HIV seropositive adults with no clinical evidence of 
tuberculosis benefit from isoniazid prophylaxis.9 This 
protection is less effective in tuberculin skin negative 
patients, probably not because they are not latently 
infected with tuberculosis, but because they have such 
serious cellular immunodeficiency that even chemo-
prophylaxis cannot protect them. The study by Zar and 
In most countries with limited resources the epidemics 
of HIV and tuberculosis continue to grow.1 Even with 
optimal treatment of active tuberculosis, the absolute 
number of tuberculosis cases will continue to rise if the 
HIV epidemic is not controlled.1 In this week’s BMJ, Zar 
and colleagues report a randomised controlled trial per-
formed in South Africa on the effect of isoniazid prophy-
laxis on mortality and the incidence of tuberculosis in 
children infected with HIV.2 The results of this study 
suggest that isoniazid prophylaxis may be an effective 
public health intervention to reduce mortality in HIV 
infected children in settings with a high prevalence of 
tuberculosis.2
Today, antiretroviral therapy programmes also offer 
new opportunities to control tuberculosis.3-5 Highly 
active antiretroviral therapy was shown to decrease 
the incidence of tuberculosis in HIV positive people 
by 70% in South Africa4 and 80% in Brazil.5 Although 
antiretroviral therapy is likely to reduce the incidence 
of tuberculosis in people infected with HIV, mathemati-
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milk fortified with ferrous gluconate and zinc oxide 
reduced anaemia and iron deficiency.
Notwithstanding the benefits, milk fortification is 
expensive, and central processing and commodity 
costs are high. The usefulness, cost effectiveness, and 
sustainability of this approach must be evaluated at 
scale in representative populations. A few examples are 
available of efforts to improve complementary feeding 
practices as a way of increasing micronutrient intake. 
The remarkable benefits on growth seen in Peru after 
a nutrition and health education intervention delivered 
by the health system suggest that this may be feasible 
in communities where food availability and choice are 
not a problem.14 However, this approach may not work 
in places like India, where poverty and religious beliefs 
preclude adequate intake of micronutrient containing 
foods such as meat and poultry products. If the avail-
ability of food can be ensured through appropriate 
financial support and social insurance schemes, these 
interventions are the most logical way to provide iron 
and zinc to young children.
Availability of fortified milk poses a risk to programmes 
for the support of exclusive breastfeeding in such coun-
tries, so their use and promotion must be strictly targeted 
and monitored. There is therefore a pressing need to 
evaluate such interventions in large scale community 
studies before they can be recommended.
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and IMAI training modules.13 These are currently 
implemented in a growing number of settings, such as 
Uganda and Senegal, which will report back on their 
effectiveness in operational circumstances.
Antiretroviral therapy programmes could also favour 
the transmission of tuberculosis. Firstly, nosocomial 
transmission of tuberculosis could occur, especially in 
large scale and centralised HIV treatment centres that 
lack proper preventative measures. Secondly, the total 
number of people living with HIV and at increased risk 
for developing tuberculosis in the region will increase. 
Finally, if patients do not adhere to their treatment, if 
inappropriate retroviral regimens are used, or if a reli-
able supply of antiretroviral therapy is not maintained 
some patients may remain severely immunodeficient 
and susceptible to developing tuberculosis and drug 
resistance.
The increased access to antiretroviral therapy in 
resource poor settings offers important opportunities for 
controlling tuberculosis. Access to antiretroviral therapy 
seems to be changing the health seeking behaviour of the 
population. This could lead to earlier diagnosis and treat-
ment of HIV and tuberculosis. Collaboration between 
those implementing HIV and tuberculosis control pro-
grammes, needed to scale up the implementation of 
antiretroviral therapy, will hopefully lead to the strength-
ening of the healthcare infrastructure in general.
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colleagues shows that isoniazid prophylaxis in children 
(most of whom were not taking antiretroviral therapy) 
reduced mortality compared with placebo (median 
follow-up 5.7 months: 11 (8.3%) v 21 (16%); hazard ratio 
0.46, 95% confidence interval 0.22 to 0.95) and reduced 
the incidence of tuberculosis. Antiretroviral therapy reac-
tivates the immune system and therefore may increase 
the protective effect of tuberculosis chemoprophylaxis. 
A study in Brazil showed that a combination of highly 
active antiretroviral therapy and isoniazid prophylaxis 
reduced the incidence of tuberculosis to 0.6 per 100 
person years of follow-up.10
Effective case finding and treatment are crucial to 
controlling tuberculosis. However, in most instances 
the diagnosis of tuberculosis in people with HIV is 
delayed, which may foster its transmission in the com-
munity. Many factors contribute to this delay such as 
insufficient awareness about tuberculosis, stigma asso-
ciated with tuberculosis and HIV, insufficient access 
to good health care, lack of confidence in healthcare 
services, and difficulties in diagnosing tuberculosis, 
particularly in people with HIV. Increased access to 
antiretroviral therapy could positively influence some 
of these factors. Indeed, in many countries where free 
antiretroviral therapy is available, treatment centres are 
overwhelmed by patients. Moreover in countries with 
a high seroprevalence of HIV and increasing access to 
antiretroviral therapy, community efforts to fight both 
HIV and tuberculosis are growing.
Before initiating antiretroviral therapy patients should 
be evaluated for signs or symptoms of tuberculosis. If 
tuberculosis is diagnosed, treatment for the disease 
should probably be started before initiating antiret-
roviral therapy, as this would decrease the risk of the 
tuberculosis immune reactivation inflammatory syn-
drome.11 Thus, an increase in the capacity to diagnose 
tuberculosis is needed for the successful implementation 
of antiretroviral therapy.
In countries with limited resources, antiretroviral ther-
apy is usually not started until patients have advanced 
HIV disease. Consequently, many people with HIV 
already have tuberculosis. For example, at the Infec-
tious Diseases Institute in Kampala, Uganda, the mean 
CD4 lymphocyte count of patients starting antiretroviral 
therapy is 65!106/l and 14% of these patients have a his-
tory of tuberculosis.12 With increasing access to antiret-
roviral therapy, more asymptomatic patients with HIV 
may have access to such treatment. To facilitate early 
antiretroviral therapy, CD4 lymphocyte counting should 
be available wherever HIV testing is performed.
Decentralising CD4 lymphocyte counting will lead 
to earlier initiation of antiretroviral therapy. This will 
decrease the risk of patients developing tuberculosis 
and potentially reduce the incidence of tuberculosis in 
communities where HIV and tuberculosis are prevalent. 
However, this decentralisation will require extra staff, 
including qualified nurses and counsellors, and even lay 
counsellors if not enough health staff are available.
As a way of achieving this objective the World Health 
Organization developed the integrated management 
of adolescent and adult illnesses (IMAI) guidelines 
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Surgery for cataract
Reorganisation of in-house services is an efficient way to improve quality and 
increase volume
Cataract is the most common cause of visual impair-
ment throughout the world.1 In the United Kingdom 
the prevalence of visually significant cataract is 30% in 
people over the age of 65.2 Modern cataract surgery 
rapidly improves vision, can be performed as a day case 
procedure, and has a low rate of complications. The 
demand for cataract surgery in the UK exceeds its avail-
ability, and the best way to organise services to meet the 
demand is unclear. In this week’s BMJ a study by Tey 
and colleagues reports on how reorganisation of their 
existing National Health Service ophthalmic service 
increased the quality and volume of cataract surgery.3
The demand for cataract operations has increased, 
and the number of procedures performed annually in 
the UK increased by 50% between 1990 and 1997.4 
However, the rate of cataract surgery for older peo-
ple in the UK remained disproportionately low. In 
1997 it was still fewer than 2000 per 100 000 for over 
65 year olds compared with a government target of 
3200 per 100 000, and waiting times were longer than 
200 days.5 The government responded to the deficit 
by increasing funding for cataract surgery.4 The main 
aims were to improve referral to secondary care, reduce 
the number of patient visits before and after surgery, 
and encourage development of efficient, high volume, 
cataract only operating lists. Cataract surgery would 
be performed not only in general ophthalmic operat-
ing theatres, but also in cataract treatment centres that 
could be part of the normal local ophthalmic service or 
in the independent sector. By 2003 annual targets for 
cataract operations were exceeded,6 and by 2005 the 
maximum wait for surgery was less than three months 
for all age groups.6 7 
Despite these promising results the role of the inde-
pendent sector, specifically the contribution of independ-
ent sector treatment centres in increasing capacity, has 
been questioned. A report by the House of Commons 
Heath Committee concluded that they were poorly inte-
grated into the NHS, and that the decision to go ahead 
with phase one of the independent sector treatment cen-
tre programme was “a leap into the dark.”8
An independent sector treatment centre operating in 
an area with no capacity problem is a prime example of 
poor integration. It may result in little or no reduction 
in the waiting time for cataract surgery at the expense of 
financial destabilisation of local NHS hospitals.8 Also, 
there will be a loss of training opportunities for junior 
doctors in the long term, which may lead to a shortage 
of appropriately trained surgeons.9
Separating elective and emergency care does have 
benefits. For hospital cataract services, much can be 
gained from having an in-house treatment centre, 
where only cataract operations are performed.3 10 The 
study of Tey and colleagues describes such a model, 
which has improved the efficiency and quality of care 
and increased training opportunities for junior ophthal-
mologists.9 This model can be set up at relatively low 
cost, it increases throughput, and more importantly it 
is fully integrated with the local service.9 Long term 
results from a similar treatment centre show that the 
effect can be maintained, with rates of access to cataract 
surgery among the highest in the country.10 11 During the 
past three years the number of people having cataract 
surgery has stabilised in England and Wales and waiting 
times have shortened—median waiting times are around 
70 days.6 Currently 95% of UK cataract procedures are 
still performed in (NHS) hospitals, but should more 
cases be performed in treatment centres?7 Similar 
problems with cataract surgery waiting times occurred 
in Canada, and were resolved by using high volume 
cataract centres. Waiting times have reduced but there 
are concerns that this may be at the expense of funding 
for other ophthalmic treatments, and ultimately there 
will be excessive unused capacity.12 
The study by Tey and colleagues suggests that treat-
ment centres within hospitals provide value for money 
and can deal with the surgical backlogs efficiently and 
effectively. However, the UK government is keen to 
extend patient choice and increase the number of inde-
pendent treatment centres. Independent sector treat-
ment centres certainly have a role in improving access 
to all forms of surgery, but only if they can integrate into 
local services and take into account local needs.
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Renaming schizophrenia
Diagnosis and treatment are more important than semantics
Recent reports in the media have called for schizophre-
nia to be “abolished as a concept” because it is scien-
tifically meaningless.1 This is not the first time that the 
validity of this diagnostic entity has been challenged, 
and it will not be the last until the cause of the disorder 
and its precise pathophysiology are known.
The current system of psychiatric diagnosis can-
not describe definitive disease entities because of our 
inability to demonstrate “natural” boundaries between 
disorders. However, as Kendell and Jablensky point 
out, “thoughtful clinicians have long been aware that 
diagnostic categories are simply concepts, justified only 
by whether they provide a useful framework for organ-
ising and explaining the complexity of clinical experi-
ence in order to derive inferences about outcome and 
to guide decisions about treatment.”2 In this context, 
the charge that schizophrenia does not define a specific 
illness is clearly unwarranted. Although the validity of 
the diagnosis remains to be established, its diagnostic 
reliability and usefulness are indisputable.
For more than 100 years schizophrenia has been 
an integral part of our nosology and has facilitated 
research and treatment of people affected by this dis-
ease.3 4 People qualify for the diagnosis if their clini-
cal signs and symptoms conform to the operational 
diagnostic criteria that define schizophrenia. Many 
studies have shown that these diagnostic criteria can 
be applied reliably and accurately by trained mental 
health professionals.5 6 Although a diagnosis of schizo-
phrenia depends on the presence of a pattern of symp-
toms (such as delusions, hallucinations, disorganised 
speech, disorganised or catatonic behaviour, and nega-
tive symptoms such as lack of motivation), evidence 
shows that these are manifestations of brain pathol-
ogy.7 Schizophrenia is not caused by disturbed psy-
chological development or bad parenting. Compared 
with normal controls, people with schizophrenia have 
abnormalities in brain structure and function seen on 
neuroimaging and electrophysiological tests. In addi-
tion, the evidence that vulnerability to schizophrenia 
is at least partly genetic is indisputable.8 
Once a diagnosis of schizophrenia is made, the treat-
ing clinician has a wide array of treatment options 
available, which have been tested empirically on simi-
lar groups of people. Furthermore, the doctor will also 
have access to the huge body of empirical data that 
characterises this condition including its course, treat-
ment response, outcome, and family history. This is 
important because evidence shows that early interven-
tion may improve outcome.9 The diagnosis also helps 
when explaining to the patient and their family the 
nature of the problem, the range of treatments and 
outcomes, and the assistance available from support 
groups.
Of course, diagnostic labels have potential disad-
vantages. If a diagnosis of schizophrenia is mistakenly 
applied, the patient will receive the wrong treatment 
and potentially have the stigma of having a mental 
illness. For example, if a patient with a toxic (such 
as phencyclidine induced) psychosis is misdiagnosed 
with schizophrenia, he or she may be given a long and 
unnecessary course of antipsychotic drugs. To avoid 
this situation, psychiatric diagnoses have built-in safe-
guards in the form of exclusion criteria that prevent 
a diagnosis from being made if certain conditions are 
present (for example, a diagnosis of schizophrenia is 
not permitted unless psychotic symptoms persist for a 
substantial period of time after the person has stopped 
using the drug in question).
Concerns about potential stigma associated with 
having a serious mental illness have resulted in pro-
posals to change the name of schizophrenia. “Integra-
tion disorder” and “dopamine dysregulation disorder” 
have been suggested as possible alternatives.10 Unfor-
tunately, changing the name of the condition (or even 
abolishing the concept) will not affect the root cause 
of the stigma—the public’s ignorance and fear of peo-
ple with mental illness. Renaming may even have the 
unintended effect that the person, rather than the ill-
ness, is blamed for the symptoms.11
Ultimately, we must gain a more complete under-
standing of the causes and pathophysiological mecha-
nisms underlying schizophrenia. Only then can we 
replace the way we characterise schizophrenia with 
a diagnosis that more closely conforms to a specific 
brain disease. In the meantime, we can be confident 
and grateful that the benefits conferred by the concept 
of schizophrenia far outweigh any perceived disad-
vantages.
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